InChI key
FQCKMBLVYCEXJB-MNSAWQCASA-L
InChI
1S/2C33H35FN2O5.Ca/c2*1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;/h2*3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);/q;;+2/p-2/t2*26-,27-;/m11./s1
assay
≥97% (HPLC)
form
powder
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic), protect from light
color
white
solubility
methanol: 10 mg/mL, clear, colorless, DMSO: 100 mg/mL, clear, colorless, ethanol: 2 mg/mL, clear, colorless, water: insoluble
shipped in
ambient
Quality Level
General description
A cell-permeable ring-opened pentasubstituted pyrrolyl-dihydroxyheptanoate compound that acts as a highly potent and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (IC50 = 7.5 nM in rat liver microsomes). Reduces cholesterol synthesis and increases the expression LDL receptors in hepatocytes. Exhibits anti-inflammatory and anti-oxidant properties. Acts as a hypotensive agent that acts by enhancing flow mediated dilation. Shown to overcome carboplatin resistance in non-small-cell lung carcinomas possibly by suppressing Akt activity and upregulating TIMP-1.
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Chen, J., et al. 2012. Int. J. Biochem. Cell Biol., in press.
Tycinska, A.M., et al. 2011. Arch. Med. Sci.7, 955.
Law, M.R., et al. 2003. BMJ326, 1423.
Youssef, S., et al. 2002. Nature420, 78.
Burnett, J.R., et al. 1998. Arterioscler. Thromb. Vasc. Biol.18, 1906.
Bustos, C., et al. 1998. J. Am. Coll. Cardiol.32, 2057.
Bocan, T.M.A., et al. 1992. Biochimica et Biophysica Acta1123, 133.
Roth, B.D., et al. 1991. J. Med. Chem.34, 463.
Shaw, M.K., et al. 1990. Biochem. Biophys. Res. Commun.170, 726.
Tycinska, A.M., et al. 2011. Arch. Med. Sci.7, 955.
Law, M.R., et al. 2003. BMJ326, 1423.
Youssef, S., et al. 2002. Nature420, 78.
Burnett, J.R., et al. 1998. Arterioscler. Thromb. Vasc. Biol.18, 1906.
Bustos, C., et al. 1998. J. Am. Coll. Cardiol.32, 2057.
Bocan, T.M.A., et al. 1992. Biochimica et Biophysica Acta1123, 133.
Roth, B.D., et al. 1991. J. Med. Chem.34, 463.
Shaw, M.K., et al. 1990. Biochem. Biophys. Res. Commun.170, 726.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
存储类别
10-13 - German Storage Class 10 to 13
法规信息
监管及禁止进口产品
此项目有
Peixiang Zhang et al.
Nature communications, 15(1), 5571-5571 (2024-07-03)
Statin drugs lower blood cholesterol levels for cardiovascular disease prevention. Women are more likely than men to experience adverse statin effects, particularly new-onset diabetes (NOD) and muscle weakness. Here we find that impaired glucose homeostasis and muscle weakness in statin-treated
G E Callera et al.
Methods in molecular biology (Clifton, N.J.), 1527, 251-269 (2017-01-25)
This chapter outlines protocols to evaluate protein localization, recruitment or phosphorylation levels in cholesterol/sphingolipids-enriched cell membrane domains and recommends experimental designs with pharmacological tolls to evaluate potential cell functions associated with these domains. We emphasize the need for the combination
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持